[Form 4] Quest Diagnostics Inc. Insider Trading Activity

Rhea-AI Filing Summary

Patrick Plewman, SVP for Diagnostic Services at Quest Diagnostics Inc. (DGX), exercised non-qualified stock options and sold shares under a Rule 10b5-1 plan on 08/06/2025. The filing shows an exercise of 3,560 options at an exercise price of $86.63 and subsequent sales of 3,560 shares at $175 and an additional 1,975 shares at $175. Following these transactions the reporting person beneficially owned 19,219 shares and the reported option grant counts are 0. The filing notes the exercise and sales were effected pursuant to a Rule 10b5-1 sales plan, that the option vested in three annual installments beginning Feb 18, 2020, and that the beneficial ownership total includes exempt purchases under the company stock purchase plan since the last Form 4.

Positive

• Transactions executed pursuant to a Rule 10b5-1 plan, indicating pre-planned, compliant insider trading
• Clear disclosure of quantities and prices: exercise at $86.63 and sales at $175 are explicitly reported
• Vesting history provided for the option grant, improving transparency

Negative

• Insider beneficial ownership decreased by 5,535 shares following the reported sales
• Reported derivative position from this grant is now zero, reducing future reported alignment from these options

Insights

Corporate Governance Expert

TL;DR: Routine, pre-planned option exercise and sale under a Rule 10b5-1 plan; transparent disclosure but reduces insider stake.

The Form 4 documents a planned exercise of 3,560 non-qualified options at $86.63 and the sale of those shares plus an additional 1,975 shares at $175, executed pursuant to an established 10b5-1 plan. From a governance standpoint, use of a 10b5-1 plan and clear reporting supports compliance and transparency. The transactions materially reduce the reporting person’s direct holdings by 5,535 shares; while routine, such sales modestly lower insider alignment with shareholders. The filing includes vesting history for the option grant and notes exempt purchases under the employee purchase plan.

Securities Analyst

TL;DR: Insider exercised options and sold shares at stated prices under a pre-arranged plan; this is likely neutral for DGX investors.

The Form 4 shows an exercise of options and contemporaneous sales executed on 08/06/2025 under a 10b5-1 plan. The derivative position tied to this grant is reported as 0 following the transactions. The transaction sizes are modest in absolute share counts and were pre-planned, indicating limited market-impact significance. Reporting is complete and provides vesting dates for the grant, supporting clarity around timing and authorization of the trades.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Plewman Patrick

(Last) (First) (Middle)

500 PLAZA DRIVE

C/O QUEST DIAGNOSTICS INC

(Street)

SECAUCUS NJ 07094

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
QUEST DIAGNOSTICS INC [ DGX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	SVP for Diagnostic Services

3. Date of Earliest Transaction (Month/Day/Year)
08/06/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	08/06/2025		M(1)		3,560	A	$86.63	24,745	D
Common Stock	08/06/2025		S(1)		3,560	D	$175	21,185	D
Common Stock	08/06/2025		S(1)		1,975	D	$175	19,219(2)	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Non-Qualifed Stock Option (right to buy)	$86.63	08/06/2025		M(1)			3,560	(3)	02/18/2029	Common Stock	3,560	$86.63	0	D

Explanation of Responses:

1. This exercise and sale reported were effected pursuant to a Rule 10b5-1 sales plan adopted by the reporting person.

2. The amount includes exempt purchases made under the Company's stock purchase plan since the date of the last filing on Form 4.

3. The options vested in three annual installments beginning with the first on February 18, 2020, the second on February 18, 2021 and the final on February 18, 2022.

Remarks:

	Sean D. Mersten, Attorney in Fact for Patrick Plewman	08/08/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did Patrick Plewman (DGX) report on Form 4?

The filing reports an exercise of 3,560 non-qualified stock options at $86.63 and sales of 3,560 and 1,975 Quest Diagnostics shares at $175 on 08/06/2025.

Were the transactions part of a pre-arranged plan for DGX insider trades?

Yes. The exercise and sales were effected pursuant to a Rule 10b5-1 sales plan adopted by the reporting person.

How many Quest Diagnostics shares does the reporting person own after these transactions?

Following the reported transactions the reporting person beneficially owned 19,219 shares.

What happened to the option grant reported on the Form 4?

The option grant tied to the reported exercise is shown with 0 derivative securities beneficially owned following the transactions; the options vested in three installments beginning Feb 18, 2020.

Does the filing mention other purchases?

Yes. The filing states the reported beneficial ownership amount includes exempt purchases made under the company’s stock purchase plan since the date of the last Form 4 filing.